Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Pfizer Granted China Approval for Children's Pneumonia Vaccine

publication date: Nov 2, 2016
Pfizer received CFDA approval to market Prevenar 13®, a pneumococcal 13-valent conjugate vaccine, in China. The vaccine immunizes children (six weeks to 15 months) against invasive diseases (bacteremic pneumonia, meningitis, septicemia, and bacteremia) caused by 13 serotypes of pneumonia. In April 2015, the CFDA refused to approve an update of Pfizer's marketing application for an earlier form of the vaccine, Prevenar 7, the only vaccine Pfizer marketed in China. In response, Pfizer closed its China commercial vaccine operation, laying off 200 workers. More details....

Stock Symbol: (NYSE: PFE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital